Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Burt Adelman is a thought leader and expert in drug development with more than 25 years of experience in the biotech industry. He was most recently executive vice president and chief medical officer at Dyax Corp., where he led the development of lanadelumab (Takhzyro), approved by the FDA and EMA for the prophylactic treatment of hereditary angioedema. Dyax was acquired by Shire in 2016. Dr. Adelman began his career at Biogen where he had an unparalleled track record, having led the successful development of important biologic therapeutics including Angiomax®, Avonex®, Amevive® and Tysabri®. At Biogen, he served in various roles including vice president of regulatory affairs, executive vice president of R&D, and executive vice president of portfolio strategy. Dr. Adelman is a member of the board of directors of Catabasis, Sirona, Clear Creek Bio, and Syntimmune, until it was sold to Alexion in 2018. He is also special advisor at Novo Ventures (US) Inc. He graduated from Cornell University Medical College, served as House Officer and Medical Resident at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) and Harvard Medical School, and completed his hematology fellowship at Brigham and Women’s Hospital (BWH). Dr. Adelman is a member of the Tufts Medical School Board of Overseers, an advisor to the Boston Biomedical Innovation Center at BWH, and a member of the investment committee of the Partners Innovation Fund (Mass General Hospital and BWH).